What is the recommended treatment for gastric vasculitis?

Treatment of Gastric Vasculitis

For gastric vasculitis, treatment depends critically on whether it is part of systemic ANCA-associated vasculitis (AAV) or isolated to the stomach—if systemic AAV with organ-threatening disease, initiate combination therapy with glucocorticoids plus rituximab or cyclophosphamide; if truly isolated gastric vasculitis, surgical resection may be curative and avoids long-term immunosuppression.

Determining the Clinical Context

The first critical step is establishing whether gastric vasculitis represents:

1. Systemic vasculitis with gastric involvement (most common)
2. Isolated gastric vasculitis (extremely rare)

Diagnostic Workup Required

• ANCA testing: Both PR3-ANCA and MPO-ANCA using high-quality antigen-specific assays 1
• Biopsy confirmation: Strongly recommended to establish vasculitis diagnosis 1
• Systemic evaluation: Screen for renal (glomerulonephritis), pulmonary (alveolar hemorrhage), neurologic, and other organ involvement
• Imaging: CT or endoscopic ultrasound to assess extent of gastric involvement

Treatment Algorithm

If Part of Systemic ANCA-Associated Vasculitis (GPA/MPA)

Gastric involvement in AAV constitutes organ-threatening disease requiring aggressive immunosuppression 2.

Remission Induction (First-Line)

Combination therapy with:

• Glucocorticoids PLUS Rituximab OR Cyclophosphamide 1, 3

Glucocorticoid dosing:

• Start with 50-75 mg prednisolone equivalent daily (based on body weight) 1
• Consider reduced-dose regimen: IV methylprednisolone pulses (3 daily doses, max 3 gm total) followed by 1 week high-dose oral glucocorticoids 3
• Taper to 5 mg/day by 4-5 months 1

Rituximab dosing:

• 375 mg/m² IV weekly × 4 doses OR
• 1,000 mg IV on days 1 and 15 3

Cyclophosphamide dosing:

• Up to 2 mg/kg/day oral for 3-6 months OR
• 15 mg/kg IV every 2 weeks × 3 doses, then every 3 weeks × at least 3 doses 3

Key consideration: Rituximab is preferred for relapsing disease 1. The reduced-dose glucocorticoid regimen provides similar efficacy with decreased infection risk 3.

Adjunctive Therapy

• Avacopan (C5a receptor antagonist) may be added to rituximab or cyclophosphamide to substantially reduce glucocorticoid exposure 1
• Plasma exchange: NOT routinely recommended for gastrointestinal vasculitis; reserved for severe glomerulonephritis (creatinine >300 µmol/L) 1

Remission Maintenance

After achieving remission:

• Rituximab is preferred: 500 mg IV every 6 months or 1 gm IV every 4 months 1, 3
• Alternatives: Azathioprine (up to 2 mg/kg/day) or methotrexate (up to 25 mg/week) 1, 3
• Duration: 24-48 months minimum; longer for relapsing disease 1

Refractory Disease

If inadequate response to initial therapy 4, 2:

• Reassess diagnosis and exclude mimickers (vascular malformations, infections) 5
• Consider switching from cyclophosphamide to rituximab or vice versa
• High-dose glucocorticoids with cyclophosphamide or rituximab for severe cases 4, 2
• Refer to specialized vasculitis center 1

If Isolated Gastric Vasculitis (Extremely Rare)

Only one case of truly isolated gastric vasculitis has been reported 6.

Surgical approach:

• Gastric resection of affected tissue may be curative 6
• Avoids long-term immunosuppression and its complications
• Provides definitive histologic diagnosis and excludes scirrhous gastric carcinoma

Post-operative monitoring:

• Long-term surveillance for development of systemic vasculitis
• Serial ANCA testing and clinical assessment

Critical Pitfalls to Avoid

1. Misdiagnosis: Gastric vasculitis can mimic scirrhous gastric carcinoma, inflammatory bowel disease, or vascular malformations 6, 5. Always obtain tissue diagnosis.

2. Delayed treatment: Gastrointestinal vasculitis carries high mortality risk from bowel ischemia and perforation 2, 7. Do not delay immunosuppression while awaiting complete workup if clinical suspicion is high.

3. Glucocorticoid monotherapy: Inadequate for organ-threatening disease 3. Always combine with rituximab or cyclophosphamide.

4. Premature discontinuation: Maintain remission therapy for minimum 24 months to prevent relapse 1.

5. Overlooking systemic involvement: Even if gastric symptoms predominate, thoroughly evaluate for renal, pulmonary, and neurologic disease 2.

Special Considerations

Secondary vasculitis contexts (e.g., SLE, antiphospholipid syndrome):

• High-dose glucocorticoids remain cornerstone 8, 4
• Add cyclophosphamide or rituximab for severe cases 4, 2
• Anticoagulation essential for antiphospholipid syndrome 8

Monitoring treatment response:

• Clinical assessment is primary determinant, not ANCA titers or B-cell counts alone 1
• Serial endoscopy may be needed to assess mucosal healing
• Monitor for treatment-related complications (infections, malignancy)